Temoporfin-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: A multicenter study.

Head & Neck Pub Date : 2010-12-01 DOI:10.1002/hed.21368

Ing Bing Tan, Gilles Dolivet, Philippe Ceruse, Vincent Vander Poorten, Gerda Roest, Winrich Rauschning

{"title":"Temoporfin-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: A multicenter study.","authors":"Ing Bing Tan, Gilles Dolivet, Philippe Ceruse, Vincent Vander Poorten, Gerda Roest, Winrich Rauschning","doi":"10.1002/hed.21368","DOIUrl":null,"url":null,"abstract":"Background: The aim of this study was to confirm the efficacy of temoporfin (Foscan)-mediated photodynamic therapy (PDT) in patients with end-stage head and neck squamous cell carcinoma (HNSCC).Methods: Thirty-nine patients with recurring HNSCC lesions ≤10 mm in depth were injected with temoporfin, followed by illumination of the tumor surface.Results: Of 39 treated patients, 19 achieved complete response, 2 partial response, 5 stable disease, 5 had progressive disease, and 8 patients were nonevaluable. Thus, in the per-protocol analysis, the response rate was 68%. Of the treated patients 54% had a response. Median survival was significantly longer for responders (37 months) than for nonresponders (7.4 months). Nine patients were alive at 3.7 to 6.5 years (median, 4.8 years) post-treatment, 7 free of disease. No major toxicities were observed.Conclusions: Patients with advanced HNSCC with lesions ≤10 mm in depth, who have exhausted other treatment options, can achieve significant local control and survival benefit from temoporfin-mediated PDT.","PeriodicalId":501638,"journal":{"name":"Head & Neck","volume":" ","pages":"1597-604"},"PeriodicalIF":0.0000,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hed.21368","citationCount":"87","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head & Neck","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.21368","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 87

Abstract

Background: The aim of this study was to confirm the efficacy of temoporfin (Foscan)-mediated photodynamic therapy (PDT) in patients with end-stage head and neck squamous cell carcinoma (HNSCC).

Methods: Thirty-nine patients with recurring HNSCC lesions ≤10 mm in depth were injected with temoporfin, followed by illumination of the tumor surface.

Results: Of 39 treated patients, 19 achieved complete response, 2 partial response, 5 stable disease, 5 had progressive disease, and 8 patients were nonevaluable. Thus, in the per-protocol analysis, the response rate was 68%. Of the treated patients 54% had a response. Median survival was significantly longer for responders (37 months) than for nonresponders (7.4 months). Nine patients were alive at 3.7 to 6.5 years (median, 4.8 years) post-treatment, 7 free of disease. No major toxicities were observed.

Conclusions: Patients with advanced HNSCC with lesions ≤10 mm in depth, who have exhausted other treatment options, can achieve significant local control and survival benefit from temoporfin-mediated PDT.

查看原文本刊更多论文

临时oporfin介导的光动力治疗晚期无法治愈的头颈癌患者:一项多中心研究

背景:本研究的目的是确认临时oporfin (Foscan)介导的光动力疗法(PDT)对终末期头颈部鳞状细胞癌(HNSCC)患者的疗效。方法:39例复发性恶性鳞癌(HNSCC)病变深度≤10 mm的患者，注射温泊芬，照射肿瘤表面。结果:39例患者中，19例完全缓解，2例部分缓解，5例病情稳定，5例病情进展，8例无法评价。因此，在每个协议分析中，响应率为68%。在接受治疗的患者中，54%的人有反应。应答者的中位生存期(37个月)明显长于无应答者(7.4个月)。9例患者治疗后存活3.7 - 6.5年(中位4.8年)，7例无疾病。未观察到重大毒性反应。结论:对于病变深度≤10mm的晚期HNSCC患者，在已耗尽其他治疗方案的情况下，采用温泊芬介导的PDT治疗可获得显著的局部控制和生存获益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Head & Neck

自引率

0.00%

发文量